Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 4/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2023110 | 0.77 | CYP3A4 (0.47) | CHRNA7KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL27183383 | 0.73 | MEN1 (0.48) | GUSBCHRNA7KDM4EMEN1ALDH1A1 | |
| SCHEMBL31527884 | 0.73 | MEN1 (0.48) | GUSBCHRNA7KDM4EMEN1ALDH1A1 | |
| SCHEMBL4656458 | 0.72 | MEN1 (0.47) | CHRNA7KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL2023234 | 0.71 | MAPT (0.44) | GUSBCHRNA7KDM4EMEN1ALDH1A1 | |
| SCHEMBL31527893 | 0.70 | CA12 (0.40) | GUSBCHRNA7ARKDM4EMEN1 | |
| SCHEMBL27183279 | 0.70 | CA12 (0.40) | GUSBCHRNA7ARKDM4EMEN1 | |
| SCHEMBL4655610 | 0.70 | ABCG2 (0.52) | MEN1ALDH1A1MAPTHPGDALOX15 | |
| SCHEMBL27676946 | 0.69 | CAPN1 (0.51) | CHRNA7MEN1ALDH1A1MAPTHPGD | |
| SCHEMBL31527674 | 0.69 | AR (0.40) | GUSBCHRNA7ARKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176471-A1 | Novel chalcone derivatives and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176471-A1 | Novel chalcone derivatives and pharmaceutical compositions comprising the same | PTGS1, PTGES2, PTGES | GUSB 2479/4885CHRNA7 3981/4885AR 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.